Table 1.
Baseline characteristics pre- and post-propensity score matching*.
| unmatched cohort (total n = 1041) | matched cohort (total n = 328) | |||||||
|---|---|---|---|---|---|---|---|---|
| Tamsulosin | Finasteride | p value | SMD | Tamsulosin | Finasteride | p value | SMD | |
| (total n = 868) | (total n = 173) | (total n = 164) | (total n = 164) | |||||
| Age [yr] | 74.1 ± 8.0 | 75.9 ± 6.7 | 0.006 | 0.20 | 75.9 ± 7.7 | 75.8 ± 6.7 | 0.862 | −0.01 |
| Body mass index [kg/m²] | 27.1 ± 3.8 | 25.8 ± 3.8 | <0.001 | −0.26 | 25.9 ± 3.6 | 25.9 ± 3.8 | 0.746 | 0.02 |
| Systolic blood pressure [mmHg] | 132.4 ± 46.3 | 129.1 ± 19.6 | 0.352 | −0.09 | 128.6 ± 21.6 | 129.5 ± 18.9 | 0.607 | 0.04 |
| Diastolic blood pressure [mmHg] | 74.5 ± 11.7 | 74.1 ± 12.3 | 0.576 | −0.03 | 75.0 ± 11.9 | 73.9 ± 11.6 | 0.346 | −0.08 |
| Heart rate [beats per min] | 72.6 ± 17.1 | 70.2 ± 13.3 | 0.209 | −0.14 | 68.3 ± 15.7 | 70.1 ± 13.5 | 0.152 | 0.10 |
| COPD | 129/868 (14.9) | 34/173 (19.7) | 0.113 | 0.10 | 33/164 (20.1) | 32/164 (19.5) | 0.890 | −0.01 |
| History of smoking | 291/868 (33.5) | 79/173 (45.7) | 0.002 | 0.20 | 72/164 (43.9) | 74/164 (45.1) | 0.824 | 0.02 |
| Hypertension | 656/868 (75.6) | 145/173 (83.8) | 0.019 | 0.17 | 134/164 (81.7) | 137/164 (83.5) | 0.662 | 0.04 |
| Hyperlipidemia | 529/868 (60.9) | 117/173 (67.6) | 0.098 | 0.12 | 108/164 (65.9) | 109/164 (66.5) | 0.907 | 0.01 |
| Diabetes mellitus | 240/868 (27.6) | 51/173 (29.5) | 0.624 | 0.03 | 42/164 (25.6) | 48/164 (29.3) | 0.458 | 0.07 |
| Aspirin | 485/868 (55.9) | 80/173 (46.2) | 0.020 | −0.16 | 80/164 (48.8) | 77/164 (46.9) | 0.740 | −0.03 |
| ACEi/ARBs | 670/868 (77.2) | 138/173 (79.8) | 0.457 | 0.05 | 134/164 (81.7) | 132/164 (80.5) | 0.778 | −0.03 |
| Beta - blockers | 661/868 (76.2) | 124/173 (71.7) | 0.212 | −0.08 | 120/164 (73.2) | 119/164 (72.6) | 0.901 | −0.01 |
| MR - antagonists | 159/868 (18.3) | 35/173 (20.2) | 0.555 | 0.04 | 29/164 (17.7) | 33/164 (20.1) | 0.573 | 0.05 |
| Statins | 611/868 (70.4) | 101/173 (58.4) | 0.002 | −0.20 | 101/164 (61.6) | 99/164 (60.4) | 0.821 | −0.02 |
| Prostate disease | ||||||||
| Benign prostatic hyperplasia | 836/868 (96.3) | 169/173 (97.7) | <0.001 | 0.07 | 154/164 (93.9) | 160/164 (97.6) | 0.005 | 0.16 |
| Prostate cancer | 32/868 (3.7) | 1/173 (0.6) | −0.20 | 10/164 (6.1) | 1/164 (0.6) | −0.29 | ||
| N/A | 0/868 (0.0) | 3/173 (1.7) | 0.13 | 0/164 (0.0) | 3/164 (1.8) | 0.14 | ||
*More details regarding characteristics of patients are provided in Table S1 in the Data Supplement. Values are expressed as mean ± SD or n/total n (%). Abbreviation: ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, COPD = Chronic obstructive pulmonary disease, N/A = not available, SMD = standard mean difference.